+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 76 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.

Age: 18Years +All GendersPhase Not Applicable
101 locations
R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and treatment experience of participants prescribed BRIUMVI4 ublituximab-xiiy for relapsing multiple sclerosis RMS in a real-world setting. The study aims to gather insights over time on how this treatment works outside of controlled clinical trials. Participants will receive BRIUMVI4 ublituximab-xiiy through intravenous infusion as part of their routine care for RMS. This observational study follows these participants longitudinally to monitor their health and treatment experience without assigning any new interventions. During the study, participants will be monitored for relapses, adverse events, and infusion-related reactions up to 96 weeks. Researchers will collect data from medical records and routine visits to assess annualized relapse rates and safety outcomes, supporting a comprehensive understanding of treatment effects in everyday clinical practice. The study duration extends until 2032, allowing for long-term follow-up.

Age: 18Years +All Genders
113 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Ifinatamab Deruxtecan I-DXd compared to the treatment chosen by a physician for people with relapsed small cell lung cancer SCLC. This Phase 3 study aims to see if I-DXd can help participants live longer than current treatments, while also examining other effects such as patient-reported outcomes, immune response, and the drugs behavior in the body. Participants will be randomly assigned to one of two groups. One group will receive I-DXd as an intravenous infusion at a dose of 12 mgkg every 21 days until the disease worsens, unacceptable side effects occur, or other stopping reasons arise. The other group will receive one of the standard treatments chosen by their doctortopotecan, lurbinectedin, or amrubicinaccording to local approved dosing guidelines and until treatment discontinuation criteria are met. During the study, participants will be closely monitored with regular imaging and assessments to track tumor response, disease progression, and quality of life using questionnaires. Safety events and immune responses will also be recorded. Pharmacokinetic samples will be collected at specified times to understand how I-DXd behaves in the body. Participants may remain in the study for up to approximately 3.7 years, allowing for long-term evaluation of outcomes and safety.

Age: 18Years +All GendersPhase 3
229 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.

Age: 12Years +All GendersPhase 3
202 locations
I

Actively Recruiting

Researchers are evaluating the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy to treat children, adolescents, and young adults with Philadelphia chromosome positive Ph or ABL-class Philadelphia chromosome-like Ph-like B-cell acute lymphoblastic leukemia B-ALL. This phase 2 trial aims to estimate event-free survival, overall survival, and safety profiles, including infections and neurotoxicity, over three years in these patients. The study also explores minimal residual disease negativity, immune function, and drug levels in the plasma and cerebrospinal fluid to better understand treatment response and outcomes. Participants receive a complex treatment plan based on their leukemia subtype. Those with Ph B-ALL receive a modified chemotherapy backbone combined with dasatinib and three cycles of blinatumomab, while patients with ABL-class Ph-like B-ALL receive similar chemotherapy with imatinib or dasatinib depending on gene fusion type. Treatment includes multiple phases such as induction, blinatumomab blocks, interim maintenance, delayed intensification, and maintenance cycles over about two years. Additional therapies like radiation, intrathecal methotrexate, and various chemotherapy drugs are also given as part of the regimen. Throughout the study, participants undergo regular evaluations including echocardiography or multigated acquisition scans during screening, as well as blood and cerebrospinal fluid collection and bone marrow biopsies at various points. Researchers closely monitor disease status, adverse events, and minimal residual disease using advanced tests. The primary outcomes measure event-free survival and adverse events up to three years, with secondary outcomes including overall survival and relapse rates. Participants remain under observation for safety and treatment response during the entire course of therapy.

Age: 366Days - 46YearsAll GendersPhase 2
161 locations
C

Actively Recruiting

Researchers are investigating treatments for newly diagnosed acute myeloid leukemia AML in children and young adults, with or without mutations in the FLT3 gene. This Phase III trial compares standard chemotherapy, which includes daunorubicin, cytarabine, and gemtuzumab ozogamicin, to therapy using a special formulation called CPX-351, which contains daunorubicin and cytarabine designed to stay longer in the bone marrow. The study also evaluates adding gilteritinib, a drug that may block abnormal FLT3 gene function and slow cancer growth, especially in patients with FLT3 mutations. The goals include comparing treatment effects, studying heart function during therapy, and assessing neurocognitive outcomes. Participants receive treatment based on risk groups and FLT3 mutation status, assigned to different study arms. Treatments include various combinations of chemotherapy drugs given intravenously, intrathecally, or orally, such as CPX-351, daunorubicin, cytarabine, gemtuzumab ozogamicin, dexrazoxane, etoposide, mitoxantrone, and gilteritinib. Treatment phases include induction, intensification, and for some, hematopoietic stem cell transplantation HSCT. Intrathecal therapies address central nervous system involvement. Gilteritinib is administered orally over extended periods in certain groups. The study also involves optional neurocognitive testing. Throughout the study, participants undergo regular assessments including blood and bone marrow samples, imaging scans like MRI and PET, and cardiac function tests such as echocardiograms. Researchers monitor minimal residual disease, survival rates, heart health, and neuropsychological function. Safety and adverse events are tracked up to three years, with some patients receiving long-term gilteritinib maintenance. The overall participation may last several years, allowing detailed evaluation of treatment impact and side effects.

Age: 6Months - 21YearsAll GendersPhase 3
206 locations
C

Actively Recruiting

Researchers are comparing the effects of adding immunotherapy drugs, brentuximab vedotin and nivolumab, to the standard chemotherapy treatment, with or without radiation, for patients diagnosed with early stage classical Hodgkin lymphoma stage I or II. This phase III trial aims to evaluate whether this combination improves survival and reduces side effects compared to standard treatment alone. The study includes both children and adults aged 5 to 60 years with newly diagnosed disease and measurable tumors. Participants first receive two cycles of the ABVD chemotherapy regimen. After treatment, imaging scans determine their early response, classifying them as rapid or slow responders and stratifying them by risk status favorable or unfavorable. Based on these factors, patients are assigned to one of eight different treatment arms involving variations of chemotherapy, immunotherapy, and involved-site radiation therapy. Treatments are given in cycles every 28 days, with some arms receiving additional cycles or radiation depending on response and risk. Throughout the trial, participants undergo regular imaging tests such as PET, CT, or MRI scans to monitor disease and treatment effects. Blood samples may also be collected. Following treatment completion, patients will be followed up with visits every 3 months for the first year, then every 6 months for two years, and annually up to 12 years. Researchers will assess outcomes including progression-free survival, overall survival, adverse events, patient-reported quality of life, fatigue, cognitive function, and long-term side effects.

Age: 5Years - 60YearsAll GendersPhase 3
419 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.

Age: 5Years - 17YearsAll GendersPhase 3
104 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of Tradipitant on treating nausea and vomiting caused by GLP-1 receptor agonist use in adults who are overweight or have class I or II obesity. This phase 3, randomized, placebo-controlled study includes healthy volunteers without serious medical issues or diabetes. The goal is to better understand how Tradipitant impacts these symptoms compared to a placebo. Participants will be randomly assigned to receive either Tradipitant or a placebo, both given as oral capsules twice daily for about two weeks. The study has two treatment arms one receiving Tradipitant and the other receiving a placebo. The study uses quadruple masking to ensure unbiased results. During the study, participants will record nausea and vomiting symptoms daily in a symptom diary. Researchers will measure the proportion of participants experiencing vomiting episodes and assess nausea severity over one week. The study will monitor safety and side effects throughout, with the total participation duration around two weeks of treatment.

Age: 18Years - 65YearsAll GendersPhase 3
10 locations

1-10 of 76

1